MiR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells

Oncogene

Volumn 33, Issue 28, 2014, Pages 3717-3729

  Takwi, A A ^a   Wang, Y M ^a   Wu, J ^a   Michaelis, M ^b   Cinatl, J ^c   Chen, T ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF KENT   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

constitutive androstane receptor; doxorubicin; MDR1; microRNA; miR 137

Indexed keywords

AZACITIDINE; CARBOXYLIC ACID; CASPASE 3; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; DOXORUBICIN; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MICRORNA; MICRORNA 137; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW METASTASIS; CANCER CELL LINE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG RESISTANCE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC REGULATION; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOLECULAR CLONING; MOUSE; NEGATIVE FEEDBACK; NEUROBLASTOMA CELL; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RNA DEGRADATION; TRANSCRIPTION INITIATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEEDBACK, PHYSIOLOGICAL; HUMANS; MALE; MICE; MICRORNAS; NEUROBLASTOMA; P-GLYCOPROTEINS; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84904249038     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.330     Document Type: Article

References (71)

1. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 2012; 83: 1112-1126.
2. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminopheninduced hepatotoxicity by the xenobiotic receptor CAR. Science 2002; 298: 422-424. (Pubitemid 35176352)
3. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007; 10: 59-67. (Pubitemid 46656478)
4. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531. (Pubitemid 38868508)
5. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355. (Pubitemid 39265675)
6. Brennecke J, Cohen S. Towards a complete description of the microRNA complement of animal genomes. Genome Biol 2003; 4: 228.
7. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011; 18: 266-272.
8. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9.
9. Passetti F, Ferreira CG, Costa FF. The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J 2009; 9: 1-13.
10. Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R et al. Differential gene and MicroRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012; 7: e45268.
11. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012; 4: 369-381.
12. Hodzic J, Giovannetti E, Calvo BD, Adema AD, Peters GJ. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1214-1222.
13. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2012doi:10.1038/onc.2012.433 1-10.
14. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216. (Pubitemid 37328872)
15. Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C et al. MYCNmediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 2004; 23: 753-762. (Pubitemid 38241276)
16. Porro A, Chrochemore C, Cambuli F, Iraci N, Contestabile A, Perini G. Nitric oxide control of MYCN expression and multi drug resistance genes in tumours of neural origin. Curr Pharm Des 2010; 16: 431-439.
17. Porro A, Haber M, Diolaiti D, Iraci N, Henderson M, Gherardi S et al. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 2010; 285: 19532-19543.
18. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535. (Pubitemid 30305902)
19. Charlet J, Schnekenburger M, Brown KW, Diederich M. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol 2012; 83: 858-865.
20. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009; 4: e7850-e7860.
21. Chen Y, Stallings RL. Differential patterns of MicroRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976-983.
22. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010; 16: 2971-2978.
23. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010; 127: 2374-2385.
24. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010; 70: 6609-6618.
25. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-2743.
26. Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently downregulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 2011; 56: 2009-2016.
27. Kozaki K-i Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-2105. (Pubitemid 351521781)
28. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L et al. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 2011; 117: 1454-1462.
29. Cinatl J, Vogel J-U, Cinatl J, Weber B, Rabenau H, Novak M et al. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 1996; 65: 90-96. (Pubitemid 26027541)
30. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69: 416-421.
31. Li Y, Wang Q, Yao X, Li Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. Eur J Pharmacol 2010; 640: 46-54.
32. Faucette SR, Sueyoshi T, Smith CM, Negishi M, LeCluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006; 317: 1200-1209. (Pubitemid 43764125)
33. Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K et al. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fasinduced murine liver injury by altering Bcl-2 proteins. Hepatology 2006; 44: 252-262. (Pubitemid 44049157)
34. Ji M, Li J, Yu H, Ma D, Ye J, Sun X et al. Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. Br J Haematol 2009; 145: 648-656.
35. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
36. Beilke LD, Aleksunes LM, Olson ER, Besselsen DG, Klaassen CD, Dvorak K et al. Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. Toxicol Lett 2009; 188: 38-44.
37. Benbow U, Maitra R, Hamilton JW, Brinckerhoff CE. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin. Clinical Cancer Res 1999; 5: 203-208. (Pubitemid 29045195)
38. Fiebig A, Zhu W, Hollerbach C, Leber B, Andrews D. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 2006; 6: 213.
39. Lahoti T, Patel D, Thekkemadom V, Beckett R, Ray SD. Doxorubicin-induced in vivo nephrotoxicity involves oxidative stress-mediated multiple pro- and anti-apoptotic signaling pathways. Curr Neurovasc Res 2012; 9: 282-295.
40. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M et al. A Novel distal enhancer module regulated by pregnane X Receptor/Constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003; 278: 14146-14152. (Pubitemid 36799961)
41. Takwi AAL, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK et al. A statinregulated microRNA represses human c-Myc expression and function. EMBO Mol Med 2012; 4: 896-909.
42. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG et al. MicroRNA- 137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008; 68: 1362-1368. (Pubitemid 351346843)
43. Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer 2011; 128: 1269-1279.
44. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA et al. Quantitation of Doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008; 324: 95-102. (Pubitemid 350294163)
45. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L et al. Upregulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 2006; 107: 1546-1554. (Pubitemid 43242393)
46. Liu J, Mao W, Ding B. Liang C-s. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 295: H1956-H1965.
47. Clair SS, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu W-j, Padi A et al. DNA damage-induced downregulation of Cdc25C Is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004; 16: 725-736. (Pubitemid 39586531)
48. Estève P-O, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci USA 2005; 102: 1000-1005. (Pubitemid 40170715)
49. Tojima H, Kakizaki S, Yamazaki Y, Takizawa D, Horiguchi N, Sato K et al. Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR. Toxicol Lett 2012; 212: 288-297.
50. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428. (Pubitemid 34587077)
51. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
52. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
53. Lujambio A. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007; 6: 1454-1458.
54. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis 2010; 31: 864-870.
55. Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 2012; 7: e39102.
56. The Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133: 484-498.
57. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
58. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899. (Pubitemid 351550859)
59. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with /antagomirs/. Nature 2005; 438: 685-689.
60. Haldar S, Basu A. Modulation of microRNAs by chemical carcinogens and anticancer drugs in human cancer: potential inkling to therapeutic advantage. Mol Cell Pharmacol 2011; 3: 135-141.
61. Kotchetkov R, Cinatl J, Blaheta R, Vogel J-U, Karaskova J, Squire J et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model. Int J Cancer 2003; 104: 36-43. (Pubitemid 36184144)
62. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R et al. Increased malignant behavior in neuroblastoma cells with acquired multidrug resistance does not depend on P-gp expression. Int J Oncol 2005; 27: 1029-1037.
63. Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R, Deimling Av et al. Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett 2007; 250: 107-116. (Pubitemid 46483847)
64. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ et al. miR-301a as an NF-[kappa]B activator in pancreatic cancer cells. EMBO J 2011; 30: 57-67.
65. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
66. Krishan A, Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res 1980; 40: 3895-3900. (Pubitemid 10030402)
67. Krishan A, Sauerteig A, Wellham LL. Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines. Cancer Res 1985; 45: 1046-1051. (Pubitemid 15111258)
68. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996; 56: 3626-3629. (Pubitemid 26272000)
69. Cherian MT, Wilson EM, Shapiro DJA. Competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem 2012; 287: 23368-23380.
70. Chen T, Tompkins LM, Li L, Li H, Kim G, Zheng Y et al. A Single amino acid controls the functional switch of human constitutive androstane receptor (CAR) 1 to the xenobiotic-sensitive splicing variant CAR3. J Pharmacol Exp Ther 2010; 332: 106-115.
71. Lin W, Wu J, Dong H, Bouck D, Zeng F-Y, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X Receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem 2008; 283: 30650-30657.